Sun Pharmaceutical Industries Limited
SUNPHARMA
Κατάταξη σε μετοχές
#525
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Τιμή μετοχής
$19.24
Τελευταίος συγχρονισμός: 2026-10-19
Κεφαλαιοποίηση
$46.15B
Αλλαγή (1 ημέρα)
-0.97%
Αλλαγή (1 έτος)
0.11%
Χώρα
IN
Εμπόριο Sun Pharmaceutical Industries Limited (SUNPHARMA)
Κατηγορία
Healthcare
Κέρδη για την Sun Pharmaceutical Industries Limited (SUNPHARMA)
Κέρδη τον Jun 2026 TTM: $1.76B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Sun Pharmaceutical Industries Limited, τα τρέχοντα κέρδη της εταιρείας είναι $1.76B. Το 2024, η εταιρεία παρουσίασε κέρδη $1.33B, αύξηση σε σχέση με των κερδών του 2023 που ήταν $1.14B. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Sun Pharmaceutical Industries Limited από 2004 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $1.76B | 9.86% |
| 2025 | $1.61B | 21.21% |
| 2024 | $1.33B | 16.34% |
| 2023 | $1.14B | 93.65% |
| 2022 | $588.17M | 54.49% |
| 2021 | $380.72M | -42.58% |
| 2020 | $663.01M | 20.88% |
| 2019 | $548.49M | 3.41% |
| 2018 | $530.42M | -62.03% |
| 2017 | $1.40B | 40.80% |
| 2016 | $992.01M | -3.13% |
| 2015 | $1.02B | 33.99% |
| 2014 | $764.30M | -3.90% |
| 2013 | $795.33M | 20.15% |
| 2012 | $661.93M | 44.90% |
| 2011 | $456.82M | 45.01% |
| 2010 | $315.02M | -17.95% |
| 2009 | $383.94M | -3.94% |
| 2008 | $399.69M | 107.87% |
| 2007 | $192.27M | 43.47% |
| 2006 | $134.02M | 39.03% |
| 2005 | $96.39M | 9.76% |
| 2004 | $87.82M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
